74.77
0.48 (0.65%)
| Previous Close | 74.29 |
| Open | 73.50 |
| Volume | 1,088,252 |
| Avg. Volume (3M) | 1,317,948 |
| Market Cap | 2,584,119,296 |
| Price / Earnings (TTM) | 17.11 |
| Price / Earnings (Forward) | 31.15 |
| Price / Sales | 4.21 |
| Price / Book | 4.72 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2026 |
| Profit Margin | 10.03% |
| Operating Margin (TTM) | 19.12% |
| Diluted EPS (TTM) | 1.42 |
| Quarterly Revenue Growth (YOY) | 48.20% |
| Quarterly Earnings Growth (YOY) | 110.60% |
| Total Debt/Equity (MRQ) | 194.67% |
| Current Ratio (MRQ) | 9.10 |
| Operating Cash Flow (TTM) | 49.38 M |
| Levered Free Cash Flow (TTM) | -84.81 M |
| Return on Assets (TTM) | 4.21% |
| Return on Equity (TTM) | 22.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | TransMedics Group, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.88 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.03% |
| % Held by Institutions | 121.56% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |